Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

CONCLUSION: We demonstrated insignificant changes in both insulin resistance and pancreatic beta cell function in clinically stable young adult Ugandan PWH on dolutegravir for 48 weeks. We add to the body of evidence demonstrating glucose metabolic safety of dolutegravir in ART naïve patients. Ugandan guidelines should reconsider restricting DTG initiation in ART naive adults at high risk for diabetes.PMID:37689695 | DOI:10.1186/s12981-023-00564-6

Source: AIDS Research and Therapy - September 9, 2023 Category: Infectious Diseases Authors: Frank Mulindwa Barbara Castelnuovo Nele Brusselaers Martin Nabwana Robert Bollinger Allan Buzibye Eva Laker Agnes Odongpiny Ronald Kiguba Jean-Marc Schwarz Source Type: research